NCT05244460

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Mercy Health Ohio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Detailed description

Patients presenting to the Emergency Department with nausea, vomiting and/or abdominal pain with a significant history of cannabis use and symptoms in a cyclic pattern will be assessed for study inclusion. After given written informed consent, patients will be treated with droperidol and diphenhydramine and symptoms will be assessed using a visual analog scale at time intervals up to 120 minutes. Patient will then be contacted at 24 and 48 hour intervals to assess symptoms on the same scale. This is a multicenter, prospective interventional study with results compared to a historical cohort using haloperidol.

Conditions

• Cannabis Hyperemesis Syndrome

Interventions

Type	Name	Description
DRUG	Droperidol Injectable Product	Treatment
DRUG	Diphenhydramine	Treatment

Timeline

• Start date: 2021-12-02
• Primary completion: 2023-01-31
• Completion: 2023-01-31
• First posted: 2022-02-17
• Last updated: 2023-01-20

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study